Medigen Biotechnology Market Cap ($141.32 Million)
Market Cap & Net Worth: Medigen Biotechnology (3176)
Medigen Biotechnology market cap. Medigen Biotechnology (TWO:3176) has a market capitalization of $141.32 Million (NT$4.49 Billion) as of November 5, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #17697 globally and #911 in its home market, demonstrating a -3.59% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medigen Biotechnology's stock price NT$32.20 by its total outstanding shares 139307000 (139.31 Million). Also see cash flow conversion of Medigen Biotechnology for how efficiently the company converts equity into cash flow.
Medigen Biotechnology Market Cap History (2015–2026)
Medigen Biotechnology market cap history from 2015 to 2026. Data shows change from $375.25 Million to $141.32 Million (-9.13% CAGR). Check today's stock price for Medigen Biotechnology for real-time trading data and today's change.
Medigen Biotechnology Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medigen Biotechnology's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Medigen Biotechnology growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.10x
Medigen Biotechnology's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $375.25 Million | $363.00 Million | -$540.93 Million | 1.03x | N/A |
| 2016 | $348.04 Million | $399.89 Million | -$568.31 Million | 0.87x | N/A |
| 2017 | $155.37 Million | $427.48 Million | -$466.75 Million | 0.36x | N/A |
| 2018 | $197.72 Million | $407.31 Million | -$442.67 Million | 0.49x | N/A |
| 2019 | $272.55 Million | $552.35 Million | -$255.72 Million | 0.49x | N/A |
| 2020 | $259.82 Million | $614.18 Million | -$337.92 Million | 0.42x | N/A |
| 2021 | $251.92 Million | $3.92 Billion | -$52.61 Million | 0.06x | N/A |
| 2022 | $147.47 Million | $1.06 Billion | -$675.87 Million | 0.14x | N/A |
| 2023 | $196.62 Million | $1.16 Billion | -$561.30 Million | 0.17x | N/A |
| 2024 | $142.20 Million | $1.37 Billion | -$204.69 Million | 0.10x | N/A |
Competitor Companies of 3176 by Market Capitalization
Companies near Medigen Biotechnology in the global market cap rankings as of November 5, 2026. Also see how large is Medigen Biotechnology's balance sheet for a full breakdown of the balance sheet.
Key companies related to Medigen Biotechnology by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Medigen Biotechnology (2015–2026)
Market capitalization of Medigen Biotechnology from 2015 to today. Between 2015 and today, Medigen Biotechnology's market cap moved from $375.25 Million to $ 141.32 Million, with a yearly change of -9.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$141.32 Million | -0.62% |
| 2025 | NT$142.20 Million | 0.00% |
| 2024 | NT$142.20 Million | -27.68% |
| 2023 | NT$196.62 Million | +33.33% |
| 2022 | NT$147.47 Million | -41.46% |
| 2021 | NT$251.92 Million | -3.04% |
| 2020 | NT$259.82 Million | -4.67% |
| 2019 | NT$272.55 Million | +37.85% |
| 2018 | NT$197.72 Million | +27.26% |
| 2017 | NT$155.37 Million | -55.36% |
| 2016 | NT$348.04 Million | -7.25% |
| 2015 | NT$375.25 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Medigen Biotechnology was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $141.32 Million USD |
| MoneyControl | $141.32 Million USD |
| MarketWatch | $141.32 Million USD |
| marketcap.company | $141.32 Million USD |
| Reuters | $141.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medigen Biotechnology
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has complete… Read more